JP Morgan Maintains Neutral on GoodRx Holdings, Raises Price Target to $7
Portfolio Pulse from Benzinga Newsdesk
JP Morgan analyst Doug Anmuth maintains a Neutral rating on GoodRx Holdings (NASDAQ:GDRX) and raises the price target from $6 to $7.

September 14, 2023 | 12:51 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
JP Morgan maintains a Neutral rating on GoodRx Holdings and raises the price target from $6 to $7.
The news is directly about GoodRx Holdings. JP Morgan's decision to maintain a Neutral rating indicates that they do not expect significant price movement in the short term. However, the increase in price target from $6 to $7 suggests a positive outlook in the longer term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100